INHIBRX BIOSCIENCES, INC. Interest Expense Nonoperating
INHIBRX BIOSCIENCES, INC. (INBX) reported Interest Expense Nonoperating of $5.69 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-13
- INHIBRX BIOSCIENCES, INC. interest expense nonoperating for the quarter ending 2026-06-30 was $5.69M, a 81.25% increase year-over-year.
- INHIBRX BIOSCIENCES, INC. interest expense nonoperating for the quarter ending 2026-03-31 was $3.51M, a 30.49% increase year-over-year.
- INHIBRX BIOSCIENCES, INC. interest expense nonoperating for the quarter ending 2025-12-31 was $3.19M.
- INHIBRX BIOSCIENCES, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $3.18M.
- INHIBRX BIOSCIENCES, INC. interest expense nonoperating for fiscal 2025 was $12.20M, a 9.60% decline from fiscal 2024.
- INHIBRX BIOSCIENCES, INC. interest expense nonoperating for fiscal 2024 was $13.49M, a 57.63% decline from fiscal 2023.
- INHIBRX BIOSCIENCES, INC. interest expense nonoperating for fiscal 2023 was $31.84M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.69M 10-Q · filed 2026-08-13 | $9.20M 10-Q · filed 2026-08-13 | $12.39M derived: sum of 3 quarters · filed 2026-08-13 | $15.57M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $3.51M 10-Q · filed 2026-05-14 | $6.69M derived: sum of 2 quarters · filed 2026-05-14 | $9.88M derived: sum of 3 quarters · filed 2026-05-14 | $13.02M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $3.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $6.37M derived: sum of 2 quarters · filed 2026-03-19 | $9.51M derived: sum of 3 quarters · filed 2026-08-13 | $12.20M 10-K · filed 2026-03-19 |
| 2025-09-30 | $3.18M 10-Q · filed 2025-11-14 | $6.32M derived: sum of 2 quarters · filed 2026-08-13 | $9.01M 10-Q · filed 2025-11-14 | $9.01M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $3.14M 10-Q · filed 2026-08-13 | $5.83M 10-Q · filed 2026-08-13 | $5.83M derived: sum of 3 quarters · filed 2026-08-13 | $5.83M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $2.69M 10-Q · filed 2026-05-14 | $2.69M derived: sum of 2 quarters · filed 2026-05-14 | $2.69M derived: sum of 3 quarters · filed 2026-05-14 | $8.05M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $0.00 derived: sum of 2 quarters · filed 2026-03-19 | $5.36M derived: sum of 3 quarters · filed 2026-03-19 | $13.49M 10-K · filed 2026-03-19 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-14 | $5.36M derived: sum of 2 quarters · filed 2025-11-14 | $13.49M 10-Q · filed 2025-11-14 | $21.71M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $5.36M 10-Q · filed 2025-08-13 | $13.49M 10-Q · filed 2025-08-13 | $21.71M derived: sum of 3 quarters · filed 2025-08-13 | $29.86M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $8.13M 10-Q · filed 2025-05-14 | $16.35M derived: sum of 2 quarters · filed 2025-05-14 | $24.50M derived: sum of 3 quarters · filed 2025-05-14 | $32.41M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $8.22M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $16.37M derived: sum of 2 quarters · filed 2025-03-17 | $24.28M derived: sum of 3 quarters · filed 2025-03-17 | $31.84M 10-K · filed 2025-03-17 |
| 2023-09-30 | $8.15M 10-Q · filed 2024-11-14 | $16.05M derived: sum of 2 quarters · filed 2024-11-14 | $23.62M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $7.91M 10-Q · filed 2024-08-13 | $15.47M 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |